Archiv
Archiv anzeigen:
bis


Ruxolitinib for Essential Thrombocythemia Resistant to Hydroxyurea

David Green, MD, PhD reviewing Harrison CN et al. Blood 2017 Aug 9

Symptom relief was more rapid with ruxolitinib versus best available therapy, but adverse effects were more frequent.


Obinutuzumab vs. Rituximab for Diffuse Large B-Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Vitolo U et al. J Clin Oncol 2017 Aug 10

Substituting obinutuzumab for rituximab during induction chemotherapy did not improve outcomes.


How Common Is Arterial Thromboembolism in Patients with Newly Diagnosed Cancer?

Joel M. Gore, MD reviewing Navi BB et al. J Am Coll Cardiol 2017 Aug 22, Yeh ETH and Chang HM. J Am Coll Cardiol 2017 Aug 22

Patients show an elevated risk for myocardial infarction and ischemic stroke 6 months after cancer diagnosis.


Decitabine vs. Azacitidine for Myelodysplastic Syndrome

David Green, MD, PhD reviewing Jabbour E et al. Blood 2017 Aug 3

Response rates were higher with decitabine, especially in higher-risk patients.


Nivolumab vs. Chemotherapy for Advanced Chemo-Naive NSCLC

Anne S. Tsao, MD reviewing Carbone DP et al. N Engl J Med 2017 Jun 22

First-line nivolumab did not prolong progression-free survival in chemo-naive patients with stage IV or recurrent PD-L1–positive non–small-cell lung cancer.


Prostatectomy vs. Observation for Localized Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Wilt TJ et al. N Engl J Med 2017 Jul 13

Surgery did not significantly lower all-cause or prostate cancer mortality.


An Antidote for Dabigatran

David Green, MD, PhD reviewing Pollack CV Jr et al. N Engl J Med 2017 Jul 11

Idarucizumab rapidly reverses the effects of dabigatran in bleeding patients and in those undergoing urgent procedures.


Progress in FLT3-Positive Acute Myeloid Leukemia

Michael E. Williams, MD, ScM reviewing Stone RM et al. N Engl J Med 2017 Jun 23

Overall survival was improved by adding midostaurin to standard induction chemotherapy.


ASCO 2017 Report — Malignant Hematology

Michael E. Williams, MD, ScM

Highlights of new treatments for myeloma, leukemia, and lymphoma


Prophylaxis for Hemophilia A with Inhibitors

David Green, MD, PhD reviewing Oldenburg J et al. N Engl J Med 2017 Jul 10, Lillicrap D. N Engl J Med 2017 Jul 10

Emicizumab prevented bleeding and improved health-related quality of life.


Archiv
Seite von 58
Editorial Member Board Empfehlungen

Prof. Dr. med. Florian Otto

Tumor- und Brustzentrum ZeTuP, St. Gallen

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Immuntherapie ist in aller Munde. Checkpoint-Inhibitoren werden bei praktisch allen onkologischen Erkrankungen erprobt und erweisen sich häufig als wirksam – zumindest für eine gewisse Zeit. Aber wie entwickelt sich eine Resistenz? Dieser Frage sind Zaretsky und Kollegen im Kontext von vier Melanompatienten unter Pembrolizumab-Therapie nachgegangen und haben Defekte im Interferon-Signalweg sowie der Antigenpräsentation in den Tumorzellen gefunden.

Kommentar weiterlesen

Management of Localized Prostate Cancer: Data at Last

Robert Dreicer, MD, MS, FACP, FASCO reviewing Hamdy FC et al. N Engl J Med 2016 Sep 14, D'Amico AV. N Engl J Med 2016 Sep 14

Mortality was similar with active monitoring, prostatectomy, or radiotherapy during 10 years of follow-up.


Hereditary Thrombophilia and Risk for Pregnancy-Associated Venous Thromboembolism

David Green, MD, PhD reviewing Gerhardt A et al. Blood 2016 Sep 9

Pregnant women with inherited thrombophilia have increased risk for VTE, independent of a family history of VTE.


Little Benefit to Extensive Breast Cancer Monitoring

William J. Gradishar, MD reviewing Accordino MK et al. J Clin Oncol 2016 Aug 20, Smith KL and Smith TJ. J Clin Oncol 2016 Aug 20

The use of >12 serum tumor marker tests and/or 4 radiographic imaging tests per year provided no survival advantage.


FOLFOX Equals or Betters Epirubicin, Cisplatin, and Fluorouracil in Esophagogastric Cancer

David H. Ilson, MD, PhD reviewing Enzinger PC et al. J Clin Oncol 2016 Aug 10

Adding epirubicin to fluorouracil/platinum-based chemotherapy resulted in greater toxicity and no clear improvement in response.


Reversing Anticoagulant-Associated Bleeding with Andexanet

David Green, MD, PhD reviewing Connolly SJ et al. N Engl J Med 2016 Aug 30

Andexanet reduced anti–factor Xa activity and restored effective hemostasis in patients with major bleeding.


Another Tool to Help Breast Cancer Patients Avoid Chemotherapy

William J. Gradishar, MD reviewing Cardoso F et al. N Engl J Med 2016 Aug 25, Hudis CA and Dickler M. N Engl J Med 2016 Aug 25

A 70-gene signature identified patients with high clinical risk and low molecular risk who achieved a 5-year survival rate of 94.7% without chemotherapy.


Daratumumab for Advanced Light Chain Amyloidosis

David Green, MD, PhD reviewing Sher T et al. Blood 2016 Aug 19

Declines in light chain levels were achieved in heavily pretreated patients.


HER2 a Potential Target in Colorectal Cancer

David H. Ilson, MD, PhD reviewing Sartore-Bianchi A et al. Lancet Oncol 2016 Jun

The HER2-targeted combination regimen of trastuzumab and lapatinib may have activity in HER2-positive, chemotherapy-refractory disease.


Resistance to Anti–PD-1 Therapy in Melanoma Patients

Jeffrey A. Sosman, MD reviewing Zaretsky JM et al. N Engl J Med 2016 Jul 13

Mutations preventing interferon-receptor signaling and antigen presentation are linked to acquired resistance.


Adjuvant S-1 for Resected Pancreatic Cancer

David H. Ilson, MD, PhD reviewing Uesaka K et al. Lancet 2016 Jun 2, Ko AH et al. Lancet 2016 Jun 2

Overall survival was significantly better with S-1 versus gemcitabine.